Choose a date range

From To

Choose one or more categories


Show only original CenterWatch stories


Baylor Research Institute, TGen Research Institute partner on precision medicine

Friday, May 22, 2015 01:57 PM

Baylor Research Institute (BRI) at Dallas, Texas and the Translational Genomics Research Institute (TGen) in Phoenix, Ariz., have inked an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

More... »

Quest Diagnostics

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015 01:50 PM

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

More... »

Foundation for Prader-Willi Research receives $1M for clinical initiatives

Friday, May 22, 2015 01:49 PM

The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), has received the organization's largest donation to date. Philanthropists Leon and Irina Shaulov contributed $1 million in support of the organization's research programs and clinical initiatives.

More... »

Center for Biomedical Research, Ackerman Cancer Center partner on clinical registry

Friday, May 22, 2015 01:47 PM

The Center for Biomedical Research (CBR) is partnering with Ackerman Cancer Center, a new proton therapy center, as part of a clinical meta-registry for clinical outcomes and long-term follow-up of cancer patients receiving proton therapy.

More... »

Eureka Therapeutics, Boehringer Ingelheim collaborate on cancer treatments

Friday, May 22, 2015 01:42 PM

California-based Eureka Therapeutics and Germany-based Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology.

More... »

Tim Dietlin joins as partner in Heidrick & Struggles' healthcare and life sciences practice

Friday, May 22, 2015 01:29 PM

Heidrick & Struggles, a provider of executive search, leadership consulting and culture shaping worldwide, has strengthened its healthcare and life sciences expertise among global practices by adding Tim Dietlin to the firm's Chicago office.

More... »

York U Researchers to look for patterns in patient data from ManagingLife's pain diary app

Thursday, May 21, 2015 02:51 PM

A digital journal of pain occurrences maintained by the users of an innovative app, Manage My Pain, will be the key source for their upcoming study, said York University psychology researchers. The app's developer ManagingLife, a privately held mobile tool developer based in Toronto, Canada, will provide the large database to York U in a collaborative effort.

More... »

PatientsLikeMe appoints Jason Johnson executive vice president and head of R&D

Thursday, May 21, 2015 02:46 PM

PatientsLikeMe has appointed Jason Johnson, Ph.D., as executive vice president and head of R&D. Johnson leads the company's research, data science and informatics teams, which focus on analyzing and merging patient-reported and other data types to develop models of disease progression and generate new insights about disease, treatments and health. Johnson reports directly to CEO Martin Coulter.

More... »

FDA approves Invega Trinza, only four-times-a-year treatment for schizophrenia

Thursday, May 21, 2015 02:27 PM

The FDA has approved under Priority Review Janssen Pharmaceuticals’ New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza. Invega Trinza, a three-month injection, is an atypical antipsychotic indicated to treat schizophrenia. Before starting Invega Trinza, patients must be adequately treated with Invega Sustenna (one-month paliperidone palmitate) for at least four months. Priority Review is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions.

More... »

BioNTech, Genmab ink immuno-oncology agreement

Thursday, May 21, 2015 02:11 PM

BioNTech, a German-based fully integrated biotechnology company developing personalized cancer immunotherapies, has signed an agreement with Genmab, a publicly traded international biotechnology company, to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech’s proprietary immunomodulatory antibodies and Genmab’s DuoBody technology platform.

More... »


May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs